Holen Sie sich die Stockscreener-App
7.98
0.13%
0.01
Schlusskurs vom Vortag:
$7.97
Offen:
$7.96
24-Stunden-Volumen:
559.29K
Relative Volume:
0.48
Marktkapitalisierung:
$367.77M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-82.60M
KGV:
-3.8738
EPS:
-2.06
Netto-Cashflow:
$-48.61M
1W Leistung:
+0.38%
1M Leistung:
+0.63%
6M Leistung:
+350.85%
1J Leistung:
+99.25%
1-Tages-Spanne:
$7.96
$7.99
1-Wochen-Bereich:
$7.94
$7.99
52-Wochen-Spanne:
$1.312
$7.99
Vigil Neuroscience Inc Stock (VIGL) Company Profile
Firmenname
Vigil Neuroscience Inc
Sektor
Branche
Telefon
857-254-4445
Adresse
100 FORGE ROAD, WATERTOWN
Vergleichen Sie VIGL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VIGL
Vigil Neuroscience Inc
|
7.98 | 367.77M | 0 | -82.60M | -48.61M | -2.06 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Vigil Neuroscience Inc Stock (VIGL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-28 | Herabstufung | Stifel | Buy → Hold |
| 2024-12-04 | Eingeleitet | William Blair | Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-10-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2023-03-31 | Eingeleitet | Mizuho | Buy |
| 2022-09-16 | Eingeleitet | Wedbush | Outperform |
| 2022-08-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-01 | Eingeleitet | Guggenheim | Buy |
| 2022-02-01 | Eingeleitet | Jefferies | Buy |
| 2022-02-01 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-01 | Eingeleitet | Stifel | Buy |
Alle ansehen
Vigil Neuroscience Inc Aktie (VIGL) Neueste Nachrichten
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Crown Electrokinetics Corp. (OTCCRKN), Elevation Oncology, Inc. (NasdaqELEV), Sitio Royalties Corp. (NYSESTR), Vigil Neuroscience, Inc. (NasdaqV - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders - MarketScreener
Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet - MSN
Vigil Neuroscience: ALSP Data Doesn't Deliver, But Sanofi Purchase Remains Intact (VIGL) - Seeking Alpha
Vigil Neuroscience fails in mid-stage study for lead asset - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LSEA, FARO, TASK, VIGL on Behalf of Shareholders - marketscreener.com
Vigil Neuroscience halts Phase 2 trial for ALSP treatment By Investing.com - Investing.com South Africa
Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease - insights.citeline.com
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Flowserve Corporation (NYSE – FLS), Streamline Health Solutions, Inc. (Nasdaq – STRM), Sitio Royalties Corp. (NYSE – STR), Vigil Neuroscience, Inc. (Nasda - Morningstar
Hold Rating on Vigil Neuroscience Inc Amidst Acquisition and Trial Outcomes - TipRanks
VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm - GuruFocus
Vigil Neuroscience (VIGL) Trial Results Impact Future Plans - GuruFocus
Vigil Neuroscience halts Phase 2 trial for ALSP treatment - Investing.com Australia
Vigil Neuroscience stock slips on trial setback (VIGL:NASDAQ) - Seeking Alpha
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Trial | VIGL Stock News - GuruFocus
Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP - marketscreener.com
Clinical Setback: Vigil Neuroscience Halts Phase 2 ALSP Trial After Iluzanebart Shows No Efficacy - Stock Titan
Northern Trust Corp Has $110,000 Stock Position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) - Defense World
Vigil Neuroscience (VIGL) Updates on Iluzanebart in Phase 2 Tria - GuruFocus
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger – PRA, AXL, SWTX and VIGL - GlobeNewswire Inc.
Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross? - sharewise
$HAREHOLDER NOTICE: The M&A Class Action Firm Continues To Investigate The MergerPRA, AXL, SWTX and VIGL - The Malaysian Reserve
HC Wainwright Has Bearish Estimate for VIGL FY2026 Earnings - Defense World
Sanofi to acquire Vigil Neuroscience in $470-M deal - MSN
Sanofi’s Acquisition Of Vigil Neuroscience - Global Legal Chronicle
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold - Defense World
Vigil Neuroscience Reports Third Quarter 2024 Financial Results and Provides Business Update - The Globe and Mail
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL St - GuruFocus
VIGL: Vigil Neuroscience's Rating Downgraded by Stifel | VIGL Stock News - GuruFocus
France: Sanofi adding to neurology pipeline with acquisition of Vigil Neuroscience - Investors in Healthcare
Vigil Neuroscience (NASDAQ:VIGL) Downgraded by HC Wainwright to “Neutral” - Defense World
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 - Investing.com Australia
VIGL: HC Wainwright Downgrades Vigil Neuroscience, Lowers Price Target | VIGL Stock News - GuruFocus
Stifel cuts Vigil Neuroscience stock rating, lowers target to $8 By Investing.com - Investing.com India
Vigil Neuroscience (VIGL) Downgraded by Stifel Following Sanofi Deal | VIGL Stock News - GuruFocus
Vigil Neuroscience (VIGL) Downgraded Amid Acquisition Plans | VIGL Stock News - GuruFocus
Hold Rating on Vigil Neuroscience Amid Sanofi Acquisition and VG-3927 Developments - TipRanks
HC Wainwright Downgrades Vigil Neuroscience to Neutral From Buy, Price Target is $8 - marketscreener.com
Sanofi to Acquire Vigil Neuroscience for $470 Million to Access Experimental Alzheimer’s Drug Targeting TREM2 - geneonline.com
Wedbush Equities Analysts Reduce Earnings Estimates for VIGL - Defense World
Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $15.00 Consensus Price Target from Brokerages - Defense World
Vigil Neuroscience Elects Directors at Annual Meeting - MSN
Vigil Neuroscience (NASDAQ:VIGL) Rating Lowered to “Hold” at Mizuho - Defense World
Vigil Neuroscience (NASDAQ:VIGL) Cut to “Hold” at Guggenheim - Defense World
Vigil Neuroscience’s (VIGL) “Market Perform” Rating Reiterated at JMP Securities - Defense World
Sanofi to Acquire Vigil Neuroscience for Up to $600M in Alzheimer’s Drug Push - USA Herald
$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - Financial Post
Finanzdaten der Vigil Neuroscience Inc-Aktie (VIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Vigil Neuroscience Inc-Aktie (VIGL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 19 '24 |
Buy |
1.68 |
5,000 |
8,400 |
222,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 18 '24 |
Buy |
1.67 |
5,000 |
8,350 |
217,687 |
| Magovcevic-Liebisch Ivana | President and CEO |
Dec 05 '24 |
Buy |
2.34 |
5,000 |
11,700 |
212,687 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):